25 May 2022 - NICE has published evidence-based recommendations on the use of romosozumab for patients with severe osteoporosis.

Romosozumab is recommended as an option for the treatment of post-menopausal women with severe osteoporosis who are at high risk of fracture, only if:

• They have had a major osteoporotic fracture (spine, hip, forearm or humerus fracture) within 24 months (so are at imminent risk of another fracture)
• UCB provides romosozumab according to the commercial arrangement

Read NICE technology appraisal guidance